Literature DB >> 33818411

Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.

Parastoo Hosseini1, Hakimeh Rahimi, Mahsa Mohammadi Najafabadi, Atousa Ghorbani, Shima Karbasi Najafabadi, Arezoo Faridzadeh, Javad Arabpour, Ehsan Khormali, Niloofar Deravi.   

Abstract

The global widespread mortality after the emergence of SARS-CoV-2 infection in China, has become a critical concern all around the world. Convalescent plasma (CP) therapy is one of the methods elevating the survival rate for COVID-19 infection cases. This technique, as a practicable therapy, was used in previous viral outbreaks including influenza, SARS and MERS. In CP therapy, the blood plasma is collected from persons rehabilitated from that specific infection in order to develop a passive immunity in other patients. Therefore, this review aimed to point out the role of CP therapy in aforementioned viral infections and illustrate different factors influencing the efficacy of CP therapy.

Entities:  

Keywords:  COVID-19; Convalescent plasma therapy; MERS; SARS; SARS-COV-2

Mesh:

Substances:

Year:  2021        PMID: 33818411

Source DB:  PubMed          Journal:  Acta Med Indones        ISSN: 0125-9326


  2 in total

Review 1.  A Review on Effectiveness of Plasma Therapy in Severe COVID-19 Patients.

Authors:  Kartik Kapil; Pramita Muntode Gharde
Journal:  Cureus       Date:  2022-09-07

Review 2.  An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19.

Authors:  Saman Yasamineh; Hesam Ghafouri Kalajahi; Pooneh Yasamineh; Yalda Yazdani; Omid Gholizadeh; Raheleh Tabatabaie; Hamed Afkhami; Fatemeh Davodabadi; Alireza Khanalipour Farkhad; Daryoush Pahlevan; Akram Firouzi-Amandi; Kazem Nejati-Koshki; Mehdi Dadashpour
Journal:  J Nanobiotechnology       Date:  2022-10-08       Impact factor: 9.429

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.